Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
ANI Pharmaceuticals Inc (ANIP)
NASDAQ:ANIP
Holding ANIP?
Track your performance easily
Earnings Data
Report Date
Feb 27, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
$1.45Last Year’s EPS
$1Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 08, 2024
|% Change Since: -8.62%
|Next Earnings Date:Feb 27, 2025
Earnings Call Sentiment|Positive
The earnings call presented a predominantly positive outlook, highlighting strong performance in the rare disease and generics segments, successful acquisition integration, and raised future guidance. However, there were notable challenges with established brand revenues and YUTIQ supply issues.Company Guidance
During ANI Pharmaceuticals' Q3 2024 earnings call, several key financial metrics and guidance were discussed. The company reported total revenues of $148.3 million, marking a 13% increase compared to the same period in 2023. This growth was driven by the strong performance of Cortrophin Gel, which generated $52.6 million in revenue, representing a 77% increase year-over-year. The generics business also saw a rise in revenues to $78.2 million, an 11% increase from the previous year. ANI completed the acquisition of Alimera in mid-September, contributing $3.9 million to revenues in the rare disease segment. The company raised its full-year 2024 revenue guidance to $594 million to $602 million and anticipates adjusted non-GAAP EBITDA of $149 million to $153 million. ANI expects Cortrophin Gel revenues to range between $196 million and $200 million for the year, while the newly acquired ILUVIEN and YUTIQ are projected to contribute $30 million to $32 million. Adjusted non-GAAP EPS is forecasted at $4.90 to $5.05, reflecting the company’s strong performance and strategic acquisitions.Record Performance in Rare Disease Segment
The rare disease asset, Cortrophin Gel, generated $52.6 million in revenues, up 77% over the third quarter of 2023. The highest number of quarterly new patient starts and unique prescribers since its launch in January 2022 was recorded.
Generics Business Growth
The generics business delivered revenues of $78.2 million, an increase of 11% over the third quarter of 2023, reflecting strong base business and new product launches.
Successful Acquisition and Integration of Alimera
The acquisition of Alimera completed on September 16, with the integration progressing well. The company expects the transaction to drive $35 million to $38 million in adjusted non-GAAP EBITDA in 2025.
Raised Full-Year Guidance
The company raised its full-year 2024 guidance, now expecting net revenues of $594 million to $602 million, up from the prior guidance of $540 million to $560 million.
---
ANIP Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ANIP Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 08, 2024 | $58.38 | $61.44 | +5.24% |
| Aug 06, 2024 | $59.16 | $63.29 | +6.98% |
| May 10, 2024 | $65.88 | $68.05 | +3.29% |
| Feb 29, 2024 | $60.28 | $67.67 | +12.26% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does ANI Pharmaceuticals Inc (ANIP) report earnings?
ANI Pharmaceuticals Inc (ANIP) is schdueled to report earning on Feb 27, 2025, TBA Not Confirmed.
What is ANI Pharmaceuticals Inc (ANIP) earnings time?
ANI Pharmaceuticals Inc (ANIP) earnings time is at Feb 27, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ANIP EPS forecast?
ANIP EPS forecast for the fiscal quarter 2024 (Q4) is $1.45.
---